Evidence-Based Treatment Pathways

Foundational lifestyle interventions

Nutrition

Multiple dietary patterns — Mediterranean, DASH, lower-carbohydrate, and structured calorie-reduced approaches — have evidence for improving cardiometabolic markers when followed consistently. No single pattern is universally superior; adherence and long-term sustainability tend to predict outcomes more than the specific macronutrient ratio.¹

Physical activity

Major guidelines recommend at least 150 minutes/week of moderate-intensity aerobic activity plus muscle-strengthening on two or more days. Physical activity improves insulin sensitivity, body composition, blood pressure, and mood independent of weight change.²

Sleep

Sleep duration under approximately seven hours per night, irregular sleep timing, and untreated sleep apnea are associated with weight gain, insulin resistance, and cardiovascular risk. Screening for sleep apnea is appropriate in patients with obesity, hypertension, or unexplained fatigue.

Behavioral interventions

Structured behavioral programs — including cognitive-behavioral strategies, group support, and digital coaching — improve outcomes when combined with nutrition and activity changes. The Diabetes Prevention Program is the best-known example.

Pharmacotherapy

GLP-1 receptor agonists and dual agonists

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and the GIP/GLP-1 dual agonist tirzepatide have demonstrated clinically meaningful weight reduction and, for certain agents, cardiovascular risk reduction in large randomized trials.³Side effects, contraindications, cost, and access vary; eligibility and choice should be discussed with a clinician.

Other agents

Additional FDA-approved options for chronic weight management include phentermine/ topiramate ER, naltrexone/bupropion, and orlistat. Metformin is widely used in type 2 diabetes and prediabetes and may have modest effects on weight in some patients.

Endoscopic therapies

Endoscopic sleeve gastroplasty (ESG) and gastric balloons are minimally invasive options performed via the upper GI tract. They generally produce less weight loss than surgery but avoid incisions and typically have shorter recovery. Long-term durability and patient selection are active areas of study.⁴

Bariatric and metabolic surgery

Sleeve gastrectomy and Roux-en-Y gastric bypass are the most-performed bariatric procedures globally. Large studies have shown durable weight loss, improvements in type 2 diabetes, hypertension, and dyslipidemia, and reductions in long-term cardiovascular events in appropriately selected patients.⁵Surgery carries operative and long-term nutritional risks and requires lifelong follow-up.

How decisions are typically made

Treatment selection is individualized. Considerations include BMI and body composition, comorbid conditions (e.g., type 2 diabetes, fatty liver), prior intervention history, psychosocial factors, patient preferences and goals, access, and cost. Many patients benefit from stepwise or combined approaches, and decisions should be revisited as circumstances change.